Program
Metronidazole
Also written as “metronidazole 1% gel”, “Metronidazole Tablet” and “metronidazole”.
Its studies are mostly in Intraabdominal Infections · Vaginosis, Bacterial · Rosacea · Appendicitis · Skin Manifestations, led by 11 companies.
Drug pageMetronidazole: every studyMany companies study it; this page follows only the 27 they lead. All 226 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 80 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Galderma Groupits history only | 40 open or running | phase 4since Feb 16, 2007 | Feb 16, 2007 | none ahead |
| S.L.A. Pharmaits history only | 40 open or running | phase 3since Jul 30, 2007 | Jul 30, 2007 | none ahead |
| Curatek Pharmaceuticalsits history only | 20 open or running | phase 3since Dec 1, 2014 | Dec 1, 2014 | none ahead |
| Par Healthits history only | 20 open or running | phase 1since Jun 16, 2011 | Jun 16, 2011 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 2since Nov 24, 2009 | Nov 24, 2009 | none ahead |
| Appili Therapeuticsits history only | 10 open or running | phase 1since Nov 6, 2017 | Nov 6, 2017 | none ahead |
| bioRASIits history only | 10 open or running | phase 3since Mar 12, 2015 | Mar 12, 2015 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 2since Mar 19, 2012 | Mar 19, 2012 | none ahead |
| Insud Pharmaits history only | 10 open or running | phase 4since Mar 4, 2015 | Mar 4, 2015 | none ahead |
| Saptalis Pharmaceuticalsits history only | 11 open or running | phase 2since Aug 8, 2025 | Aug 8, 2025 | none ahead |
Also a collaborator on its studies: Allergan Sales, AbbVie, Algorithme Pharma and PriCara, Unit of Ortho-McNeil.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Sep 12, 2005.
- Jul 20, 2011Phase 1 study in InfectionsPfizer · NCT01407016 · 6 enrolled · Japan
- Aug 26, 2011Phase 4 study in RosaceaGalderma Group · NCT01426269 · 235 enrolled · United States
- Oct 11, 2011Phase 3 study in Intraabdominal InfectionsPfizer · NCT01473836 · 38 enrolled · Japan
- Dec 19, 2011Phase 3 study in Complicated Intra-Abdominal InfectionPfizer · NCT01499290 · 493 enrolled · United States, Argentina, Bulgaria and more
- Feb 9, 2012Phase 1 study in HealthyPfizer · NCT01534247 · 28 enrolled · United States
- Mar 19, 2012Dr. Reddy's Laboratories’ first study: phase 2 study in Clostridium Difficile Associated DiarrheaNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01559545 · 60 enrolled · India
- Nov 5, 2012Phase 3 study in Complicated Intra-abdominal InfectionPfizer · NCT01726023 · 486 enrolled · China, Korea, Republic of, Vietnam
- Dec 1, 2014Curatek Pharmaceuticals’ first studies: 2 phase 3 studies in VaginitisNew to Curatek PharmaceuticalsCuratek Pharmaceuticals · NCT02308033, NCT02308007
- Mar 4, 2015Insud Pharma’s first study: phase 4 study in Vaginosis, BacterialNew to Insud PharmaInsud Pharma · NCT02392026 · 60 enrolled · United States
- Mar 12, 2015bioRASI’s first study: phase 3 study in RosaceaNew to bioRASIbioRASI · NCT02393937 · 963 enrolled · United States
- May 25, 2015Phase 2 study in Complicated Intra-abdominal InfectionsPfizer · NCT02475733 · 83 enrolled · United States, Czechia, Greece and more
- Nov 6, 2017Appili Therapeutics’ first study: phase 1 study in BioequivalenceNew to Appili TherapeuticsAppili Therapeutics · NCT03337126 · 48 enrolled · Canada
- Jan 15, 2020Phase 2 study in Pilonidal SinusS.L.A. Pharma · NCT04273997 · 80 enrolled · Turkey
- Aug 8, 2025Saptalis Pharmaceuticals’ first study: phase 2 study in Bacterial InfectionsNew to Saptalis PharmaceuticalsSaptalis Pharmaceuticals · NCT07146217 · 30 planned · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07146217Bacterial Infections · United States | 2 | Not yet recruiting | Saptalis Pharmaceuticals | Jul 2026 | 30 |
| NCT04273997Pilonidal Sinus · Turkey | 2 | UNKNOWN | S.L.A. Pharma | Feb 1, 2022 | 80 |
| NCT03337126Bioequivalence · Canada | 1 | Completed | Appili Therapeutics | Dec 13, 2017 | 48 |
| NCT02475733Complicated Intra-abdominal Infections · United States, Czechia, Greece and more | 2 | Completed | Pfizer | Jun 1, 2017 | 83 |
| NCT02393937Rosacea · United States | 3 | Completed | bioRASI | Jul 2015 | 963 |
| NCT02392026Vaginosis, Bacterial · United States | 4 | Completed | Insud Pharma | Oct 5, 2016 | 60 |
| NCT02308033Vaginitis · United States | 3 | Completed | Curatek Pharmaceuticals | Jun 2017 | 204 |
| NCT02308007Vaginitis · United States | 3 | Completed | Curatek Pharmaceuticals | Jun 2018 | 475 |
| NCT01726023Complicated Intra-abdominal Infection · China, Korea, Republic of, Vietnam | 3 | Completed | Pfizer | Mar 2015 | 486 |
| NCT01559545Clostridium Difficile Associated Diarrhea · India | 2 | Completed | Dr. Reddy's Laboratories | Feb 2013 | 60 |
| NCT01534247Healthy · United States | 1 | Completed | Pfizer | Jul 2012 | 28 |
| NCT01499290Complicated Intra-Abdominal Infection · United States, Argentina, Bulgaria and more | 3 | Completed | Pfizer | Apr 2014 | 493 |
| NCT01473836Intraabdominal Infections · Japan | 3 | Completed | Pfizer | Oct 2012 | 38 |
| NCT01426269Rosacea · United States | 4 | Completed | Galderma Group | Jun 2013 | 235 |
| NCT01407016Infections · Japan | 1 | Completed | Pfizer | Sep 2011 | 6 |
| NCT01380522Lecithin Cholesterol Acyltransferase Deficiency · Canada | 1 | Completed | Par Health | Sep 2002 | 18 |
| NCT01380509Fasting · Canada | 1 | Completed | Par Health | Sep 2002 | 28 |
| NCT01139047Skin Manifestations · United States | 4 | Completed | Galderma Group | Jun 2010 | 77 |
| NCT01139008Skin Manifestations · United States | 4 | Completed | Galderma Group | Jun 2010 | 80 |
| NCT01020877Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Nov 2001 | 38 |
| NCT01020396Vaginosis, Bacterial · United States | 2 | Completed | Teva Pharmaceutical Industries | Mar 2003 | 579 |
| NCT00774969Perianal Crohns' · United Kingdom | 1 | Completed | S.L.A. Pharma | Apr 2008 | 19 |
| NCT00774722Haemorrhoidectomy · United Kingdom | 3 | Completed | S.L.A. Pharma | Mar 2008 | 59 |
| NCT00509639Crohn Disease · United States, United Kingdom | 3 | Completed | S.L.A. Pharma | Feb 2008 | 74 |
| NCT00436527Rosacea · United States | 4 | Completed | Galderma Group | Aug 2006 | 26 |
| NCT00230971Appendicitis · Australia, China, Denmark and more | 4 | Completed | Pfizer | Sep 2008 | 473 |
| NCT00195351Appendicitis · United States, Argentina, Brazil and more | 4 | Completed | Pfizer | Feb 2008 | 467 |
How it is read
Names in the registry
- “Metronidazole”, 20 entries
- “metronidazole 1% gel”, 2 entries
- “Metronidazole Tablet”, 2 entries
- “metronidazole”, 2 entries
- “Likmez® (metronidazole) Oral Suspension”, 1 entry
Conditions, from the studies’ own filings
- Intraabdominal Infections, 7 studies
- Vaginosis, Bacterial, 4 studies
- Rosacea, 3 studies
- Appendicitis, 3 studies
- Skin Manifestations, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.